Skip to main content
TLRYTilray Brands, Inc.Sell5.4·$4.38+1.51%
SellModerate Confidence
Investment thesis

Tilray Brands shows an extreme risk/reward skew with 117% analyst upside and a passed asymmetry gate, but quality below the engine's floor, a confirmed downtrend with a death-cross block, and high short interest keep the engine's recommendation at exit.

Thesis pillars

  • Quality Below Floor Value TrapStable
  • High Asymmetry Large Analyst UpsideStable
  • Failed Momentum Confirmed DowntrendStable
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Tilray Brands, Inc. (TLRY) Stock Analysis

Inst Constrain edge

SellVALUE-TRAP 1/5ValueGrowthShortModerate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Sell if holding. Engine safety override at $4.38: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 8.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Below long-term trend.

Tilray Brands operates four segments — beverage, cannabis, distribution, and wellness — cultivating and selling medical and adult-use cannabis in Canada and Europe while producing craft beer and spirits brands including SweetWater and Breckenridge in the United States. The... Read more

QualityF-score4 / 9FCF yield-5.74%
Stop $4.08Target $8.42(analyst − 13%)A.R:R 8.4:1
Analyst target$9.68+120.9%8 analysts
$8.42our TP
$4.38price
$9.68mean
$24

Sell if holding. Engine safety override at $4.38: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 8.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.4/10, moderate confidence.

Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 21d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.

10-K grounded · weekly refresh

About Tilray Brands, Inc.

About Tilray Brands, Inc.

Tilray Brands generated $821.3 million in total net revenue during fiscal 2025 across four reportable segments — distribution (33%), cannabis (30%), beverage (29%), and wellness (8%) — with cannabis operations concentrated in Canada and medical cannabis exports reaching patients in more than 20 countries. The company's craft beverage brands, including SweetWater and Breckenridge, make it the fourth-largest craft brewer in the United States.

Tilray's cannabis business depends on licenses issued by Health Canada under the Cannabis Regulations to cultivate, process, and export medical and adult-use cannabis, with EU-GMP certified facilities in Portugal and Germany supporting international medical cannabis sales. The beverage segment sells its craft beers, ciders, and spirits — including SweetWater, Breckenridge, and Montauk — through independent distributors across the United States, while the distribution segment purchases and resells pharmaceutical and wellness products and the wellness segment markets Manitoba Harvest hemp-based foods. The company competes against numerous licensed cannabis producers in Canada, which Health Canada has authorized in the thousands, as well as established beverage companies and illicit-market cannabis suppliers that operate without regulatory compliance costs.

Show full overview

A pending U.S. regulatory shift dominates Tilray's forward risk profile: cannabis meeting the federal definition of marijuana remains a Schedule I controlled substance under the Controlled Substances Act, even as rescheduling to Schedule III remains under consideration and the 2018 Farm Bill's hemp exemption for products under 0.3% THC content faces potential FDA rulemaking. The 10-K notes Health Canada has issued approximately a thousand licenses to Licensed Producers, intensifying domestic competition, while Tilray's U.S. activity stays limited to corporate services, clinical-trial drug supply, and Farm-Bill-compliant hemp products pending any federal legalization.

See also: Healthcare · Drug Manufacturers - Specialty & Generic

From Tilray Brands, Inc.'s most recent 10-K filing, extracted July 6, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-07-08

Recent Developments — Tilray Brands, Inc.

Latest news

Generated 2026-07-08T21:03:53Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Jul 28, 202621d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Quality below floor (2.3 < 4.0)

Key Metrics

P/E (TTM)
P/E (Fwd)16.2
Mkt Cap$541M
EV/EBITDA105.7
Profit Mgn-156.7%
ROE-63.2%
Rev Growth-7.8%
Beta1.90
DividendNone
Rating analysts17

Quality Signals

Piotroski F4/9

Options Flow

P/C0.38bullish
IV93%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Unprofitable operations — net margin -156.7%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Fcf Quality
0.0
Gross Margin
1.5
Moat
3.2
Piotroski F
4.4
Current Ratio
9.4
Cash-burning: FCF -4% of revenueNo competitive moatQuality concerns

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History
0.0
Surprise Avg
0.0
Erm
5.0
Earnings Timing
5.0

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
0.1
Growth Rank
1.4
Value Rank
8.6
GatesMomentum 4.4<4.5Death cross (50MA < 200MA)A.R:R 8.4 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 21d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Speculative
RSI
33 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $4.20Resistance $5.46

Price Targets

$4
$8
A.Upside+92.2%
A.R:R8.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (2.3 < 4.0)
! momentum at 4.4 (below the engine's 4.5 threshold)
! Death cross — 50-day MA below 200-day MA

Earnings

M
M
M
M
0/4 beats
Next Earnings2026-07-28 (21d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is TLRY stock a buy right now?

Sell if holding. Engine safety override at $4.38: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 8.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $4.08. Score 5.4/10, moderate confidence.

What is the TLRY stock price target?

Take-profit target: $8.42 (+92.0% upside). Prior stop was $4.08. Stop-loss: $4.08.

What are the risks of investing in TLRY?

Quality below floor (2.3 < 4.0).

Is TLRY overvalued or undervalued?

Tilray Brands, Inc. trades at a P/E of N/A (forward 16.2). TrendMatrix value score: 9.3/10. Verdict: Sell.

What do analysts say about TLRY?

17 analysts cover TLRY with a consensus score of 3.6/5. Average price target: $10.

What does Tilray Brands, Inc. do?Tilray Brands operates four segments — beverage, cannabis, distribution, and wellness — cultivating and selling medical...

Tilray Brands operates four segments — beverage, cannabis, distribution, and wellness — cultivating and selling medical and adult-use cannabis in Canada and Europe while producing craft beer and spirits brands including SweetWater and Breckenridge in the United States. The company generated $821.3 million in total net revenue in fiscal 2025, with distribution (33%), cannabis (30%), beverage (29%), and wellness (8%) each contributing meaningfully.

Related stocks: IRWD (Ironwood Pharmaceuticals, Inc.) · ANIP (ANI Pharmaceuticals, Inc.) · INDV (Indivior Pharmaceuticals, Inc.) · COLL (Collegium Pharmaceutical, Inc.) · SUPN (Supernus Pharmaceuticals, Inc.)
Home Stocks TLRY

Latest news

Latest News

Benzinga9d agoMerger Acquisition